Mirum Pharmaceuticals, Inc. (MIRM) Earnings
Mirum Pharmaceuticals, Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.74. MIRM has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -981.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-0.40 | $-13.43 | -3257.5% | $160M | +7.9% |
| Feb 25, 2026 | $0.02 | $-0.11 | -650.0% | $149M | -0.6% |
| Aug 6, 2025 | $-0.31 | $-0.12 | +61.3% | $128M | -1.8% |
| Feb 26, 2025 | $-0.27 | $-0.49 | -81.5% | $99M | +2.9% |
| Feb 28, 2024 | $-0.34 | $-0.66 | -94.1% | $70M | +2.6% |
| Nov 2, 2023 | $-0.64 | $-0.57 | +10.9% | $48M | -30.1% |
| Aug 3, 2023 | $-0.81 | $-0.92 | -13.6% | $37M | +15.5% |
| May 4, 2023 | $-0.96 | $-0.80 | +16.7% | $32M | +10.1% |
| Mar 8, 2023 | $-0.98 | $-0.99 | -1.0% | $28M | +13.6% |
| Aug 4, 2022 | $-1.05 | $-0.84 | +20.0% | $17M | +13.4% |
| May 5, 2022 | $-1.39 | $-1.17 | +15.8% | $13M | +52.3% |
| Mar 9, 2022 | $-0.61 | $-0.92 | -50.8% | $3M | -95.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
1. Progress in rare liver disease: Uptake of Live Marley remains strong, especially in PFIC. Recent clinical readouts in PSC and hepatitis delta show potential expansions. 2. Rare genetic disease: Addition of Zolurgocertib licensed from Insight, which has an NDA accepted with priority review and PDUFA date of September 26th. 3. Commercial execution: Strong first quarter with total net product sales of $160 million, and plans to expand teams for rare liver disease into adult settings.
Guidance
1. Raised full-year 2026 net product sales guidance to $660 to $680 million. 2. Zolurgocertib NDA with PDUFA date of September 26th, expecting launch by year-end. 3. R&D expense expected to step up in 2026 for Berlovitug ahead of BLA submission next year, fully funded.
Segment performance
Total net product sales for the first quarter were approximately $160 million. Live Marley had U.S. net product sales of $84 million and international sales of $30 million, with bile acid medicines contributing $46 million. Rare liver disease and rare genetic disease are key focus areas. Revenue guidance for full-year 2026 is raised to $660 to $680 million.
Risks & headwinds
1. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially. 2. Risks related to regulatory approval, clinical trial outcomes, and market adoption of new products.
Analyst Q&A
Q: About FOP patient count and treatable patients at launch.
A: Approximately 300 identified patients in U.S., NDA for Zolurgocertib is for age 12 and over.
Q: Differentiation of Zolurgocertib vs other programs.
A: Oral once-daily ALK2 inhibitor with strong tolerability and activity profile.
Q: BD strategy and pricing for FOP.
A: Continue to find good programs, pricing to be decided closer to approval.
Q: HDV efficacy measures.
A: Focus on composite of virologic response and ALT normalization.
Q: FOP market penetration and OUS filing.
A: European filing upcoming, peak sales estimate is global.